Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Neurofibromatosis 2 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Medulloblastoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Vincristine 12Temozolomide 11Irinotecan 10Cyclophosphamide 10Melphalan 8Filgrastim 8Etoposide 7Ifosfamide 6Granulocyte Colony-Stimulating Factor 6Doxorubicin 6Vinorelbine 5Gemcitabine 5Busulfan 5Thiotepa 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Dactinomycin 4pegfilgrastim 3liposomal doxorubicin 3irinotecan sucrosofate 3fludarabine 3etoposide phosphate 3Stem Cell Transplantation 3Sirolimus 3Proton Therapy 3Cisplatin 3Carboplatin 3Bone Marrow Transplantation 3thymoglobulin 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rhabdomyosarcoma × Vascular Endothelial Growth Factor A × Clear all
NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
115 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡